Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV).

It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011.

[1] Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.

[citation needed] Faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir.

[citation needed] Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.